MONDAY, March 24 (HealthDay News) -- Women taking hormone replacement therapy who are not concerned about their risk of breast cancer are more likely to participate in a chemoprevention trial of tamoxifen than women with a greater level of worry, according to an article published in the March 20 issue of the Journal of Clinical Oncology.
Gabriella Rondanina, of the University of Genoa in Italy, and colleagues explored the factors underlying the decision of 457 women on hormone replacement therapy to participate (n=265) or to forego participation (n=192) in a proposed chemoprevention trial of low-dose tamoxifen.
The most commonly cited reasons to participate in the trial included willingness to be part of a research program, the need/desire to receive frequent medical care and the desire to contribute to medical knowledge, whereas fears of medication abuse and concerns about adverse effects were the most frequently reported reasons for declining participation in the study. Younger age, satisfaction with health care providers and lack of worry about breast cancer were associated with higher odds of participation in the trial, the investigators found.
These results "indicate that an increased worry about cancer and enhanced risk perception were inhibitory factors for trial participation, suggesting a proactive attitude towards health promotion as an important factor of trial participation," the authors conclude.
Abstract
Full Text (subscription or payment may be required)
